

Summary of Product Characteristics

1. Name of the finished pharmaceutical product

INN Name: Propofol Injectable Emulsion USP 200 mg/20 mL

Trade Name: SEDAFOL

pharmaceutical form: Injection

2. Qualitative and quantitative composition

Each Vial contains 200 mg of Propofol USP, Refined Soya been oil IV USP, Glycerol Anhydrous USP, Purified egg yolk lecithin, Edetate disodium USP, Sodium hydroxide and Water for Injection.

3. Pharmaceutical

form Dosage form:

Injection Description:

Milky white to off white emulsion present in 20 mL clear tubular glass vial, USP type-I with 20 mm grey bromobutyl serum rubber stopper and 20 mm Orange colored flip off seal.

4. Clinical particulars

4.1. Therapeutic indications

Propofol Injectable Emulsion 2% is a short-acting intravenous general anaesthetic for:

- Induction and maintenance of general anaesthesia in adults and children >3 years.
- Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia in adults and children >3 years.
- Sedation of ventilated patients >16 years of age in the intensive care unit.

4.2. Posology and method of administration

Posology

Induction of General Anaesthesia

Adults

Propofol Injectable Emulsion 2% may be used to induce anaesthesia by infusion.

Administration of Propofol Injectable Emulsion 2% by bolus injection is not recommended. Propofol Injectable Emulsion 2% may be used to induce anaesthesia by infusion but only in those patients who will receive Propofol Injectable Emulsion 2% for maintenance of anaesthesia.

In unpremedicated and premedicated patients, it is recommended that Propofol Injectable Emulsion 2% should be titrated (approximately 2 ml [40 mg] every 10 seconds in an average healthy adult by infusion) against the response of the patient until the clinical signs show the onset of anaesthesia. Most adult patients aged less than 55 years are likely to require 1.5-2.5 mg/kg of Propofol Injectable Emulsion 2%. The total dose required can be reduced by lower rates of administration (1-2.5 ml/min [20-50 mg/min]). Over this age, the requirement will generally be less. In patients of ASA Grades 3 and 4, lower rates of administration should be used (approximately 1 ml [20 mg] every 10 seconds).

Elderly

In older people the dose requirement for induction of anaesthesia with Propofol Injectable Emulsion 2% is reduced. The reduction should take into account of the physical status and age of the patient. The reduced dose should be given at a slower rate and titrated against the response.

Paediatric population

Propofol Injectable Emulsion 2% is not recommended for induction of anaesthesia in children less than 3 years of age.

For induction of anaesthesia in children over 3 years of age, Propofol Injectable Emulsion 2% should be titrated slowly until clinical signs show the onset of anaesthesia. The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg/kg body weight of Propofol Injectable Emulsion 2% for induction of anaesthesia. In younger children, dose requirements may be higher (2.5-4 mg/kg body weight).

For ASA 3 and 4 patients lower doses are recommended (see also Section 4.4)

Maintenance of General Anaesthesia

Anaesthesia can be maintained by administering Propofol Injectable Emulsion 2% by continuous infusion to prevent the clinical signs of light anaesthesia. Administration of Propofol Injectable Emulsion 2% by bolus injection is not recommended. Recovery from anaesthesia is typically rapid and it is therefore important to maintain Propofol Injectable Emulsion 2% administration until the end of the procedure.

Adults

The required rate of administration varies considerably between patients, but rates in the region of 4-12 mg/kg/h usually maintain satisfactory anaesthesia.

Elderly

When Propofol Injectable Emulsion 2% is used for maintenance of anaesthesia the rate of infusion should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.

Paediatric population

Propofol Injectable Emulsion 2% is not recommended for maintenance of anaesthesia in children less than 3 years of age.

Anaesthesia can be maintained in children over 3 years of age by administering Propofol Injectable Emulsion 2% by infusion to maintain the depth of anaesthesia required. The required rate of administration varies considerably between patients but rates in the region of 9-15 mg/kg/h usually achieve satisfactory anaesthesia. In younger children, dose requirements may be higher.

For ASA 3 and 4 patients lower doses are recommended.

Sedation During Intensive Care

Adults

For sedation during intensive care it is advised that Propofol Injectable Emulsion 2% should be administered by continuous infusion. The infusion rate should be determined by the desired depth of sedation. In most patients sufficient sedation can be obtained with a dosage of 0.3-4 mg/kg/h of Propofol Injectable Emulsion 2% (See 4.4 Special warnings and precautions for use). Propofol Injectable Emulsion 2% is not indicated for sedation in intensive care of patients of 16 years of age or younger (see 4.3 Contraindications).

It is recommended that blood lipid levels be monitored should Propofol Injectable Emulsion 2% be administered to patients thought to be at particular risk of fat overload.

Administration of Propofol Injectable Emulsion 2% should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the Propofol Injectable Emulsion 2% formulation: 1.0 ml of Propofol Injectable Emulsion 2% contains approximately 0.1 g of fat.

If the duration of sedation is in excess of 3 days, lipids should be monitored in all patients.

Elderly

When Propofol Injectable Emulsion 2% is used for sedation of anaesthesia the rate of infusion should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.

Paediatric population

Propofol Injectable Emulsion 2% is contra-indicated for the sedation of ventilated children aged 16 years or younger receiving intensive care.

Sedation for Surgical and Diagnostic Procedures

Adults

To provide sedation for surgical and diagnostic procedures, rates of administration should be individualised and titrated to clinical response.

Most patients will require 0.5-1 mg/kg over 1-5 minutes for onset of sedation.

Maintenance of sedation may be accomplished by titrating Propofol Injectable Emulsion 2% infusion to the desired level of sedation - most patients will require 1.5-4.5 mg/kg/h. In addition to the infusion, bolus administration of 10-20 mg may be used if a rapid increase in the depth of sedation is required. In patients of ASA Grades 3 and 4 the rate of administration and dosage may need to be reduced.

Elderly

When Propofol Injectable Emulsion 2% is used for sedation the rate of infusion or 'target concentration' should also be reduced. Patients of ASA grades 3 and 4 will require further reductions in dose and dose rate. Rapid bolus administration (single or repeated) should not be used in older people as this may lead to cardiorespiratory depression.

Paediatric population

Propofol Injectable Emulsion 2% is not recommended for surgical and diagnostic procedures in children aged less than 3 years.

In children over 3 years of age, doses and administration rates should be adjusted according to the required depth of sedation and the clinical response. Most paediatric patients require 1-2 mg/kg body weight of Propofol Injectable Emulsion 2% for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol Injectable Emulsion 2% infusion to the desired level of sedation. Most patients require 1.5-9 mg/kg/h Propofol Injectable Emulsion 2%. In ASA 3 and 4 patients lower doses may be required.

Method of administration

Propofol Injectable Emulsion 2% has no analgesic properties and therefore supplementary analgesic agents are generally required in addition to Propofol Injectable Emulsion 2%.

Propofol Injectable Emulsion has been used in association with spinal and epidural anaesthesia and with commonly used premedicants, neuromuscular blocking drugs, inhalational agents and analgesic agents; no pharmacological incompatibility has been encountered. Lower doses of Propofol Injectable Emulsion 2% may be required where general anaesthesia is used as an adjunct to regional anaesthetic techniques. Profound hypotension has been reported following anaesthetic induction with propofol in patients treated with rifampicin.

Propofol Injectable Emulsion 2% should not be diluted.

When Propofol Injectable Emulsion 2% is used to maintain anaesthesia, it is recommended that equipment such as syringe pumps or volumetric infusion pumps should always be used to control infusion rates.

Propofol Injectable Emulsion 2% should not be mixed prior to administration with injections or infusion fluids. However, Propofol Injectable Emulsion 2% may be co-administered via a Y-piece connector close to the injection site with the following:

- Dextrose 5% Intravenous Infusion B.P.
- Sodium Chloride 0.9% Intravenous Infusion B.P.
- Dextrose 4% with Sodium Chloride 0.18% Intravenous Infusion B.P.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Propofol Injectable Emulsion 2% contains soya oil and should not be used in patients who are hypersensitive to peanut or soya.

Propofol Injectable Emulsion 2% must not be used in patients of 16 years of age or younger for sedation in intensive care.

4.4. Special warnings and precautions for use

Propofol Injectable Emulsion 2% should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care of patients in Intensive Care).

Patients should be constantly monitored and facilities for maintenance of a patient airway, artificial ventilation and oxygen enrichment and other resuscitative facilities should be readily available at all times. Propofol Injectable Emulsion 2% should not be administered by the person conducting the diagnostic or surgical procedure.

Abuse of, and dependence on Propofol Injectable Emulsion 2%, predominantly by health care professionals, have been reported. As with other general anaesthetics, the administration of Propofol Injectable Emulsion 2% without airway care may result in fatal respiratory complications.

When Propofol Injectable Emulsion 2% is administered for conscious sedation, for surgical and diagnostic procedures, patients should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.

During induction of anaesthesia, hypotension and transient apnoea may occur depending on the dose and use of premedicants and other agents.

Occasionally, hypotension may require use of intravenous fluids and reduction of the rate of administration of Propofol Injectable Emulsion 2% during the period of anaesthetic maintenance.

As with other sedative agents, when Propofol Injectable Emulsion 2% is used for sedation during operative procedures, involuntary patient movements may occur. During procedures requiring immobility these movements may be hazardous to the operative site.

An adequate period is needed prior to discharge of the patient to ensure full recovery after use of Propofol Injectable Emulsion 2%. Very rarely, the use of Propofol Injectable Emulsion 2% may be associated with the development of a period of post-operative unconsciousness, which may be accompanied by an increase in muscle tone. This may or may not be preceded by a period of wakefulness. Although recovery is spontaneous, appropriate care of an unconscious patient should be administered.

Propofol Injectable Emulsion 2% induced impairment is not generally detectable beyond 12 hours. The effects of Propofol Injectable Emulsion 2%, the procedure, concomitant medications, the age and the condition of the patient should be considered when advising patients on:

- The advisability of being accompanied on leaving the place of administration
- The timing of recommencement of skilled or hazardous tasks such as driving
- The use of other agents that may sedate (Eg, benzodiazepines, opiates, alcohol.)

As with other intravenous anaesthetic agents, caution should be applied in patients, with cardiac, respiratory, renal or hepatic impairment or in hypovolaemic or debilitated patients. Propofol Injectable Emulsion 2% clearance is blood flow dependent, therefore, concomitant medication that reduces cardiac output will also reduce Propofol Injectable Emulsion 2% clearance.

Propofol Injectable Emulsion 2% lacks vagolytic activity and has been associated with reports of bradycardia (occasionally profound) and also asystole. The intravenous administration of an anticholinergic agent before induction, or during maintenance of anaesthesia should be considered,

especially in situations where vagal tone is likely to predominate or when Propofol Injectable Emulsion 2% is used in conjunction with other agents likely to cause a bradycardia.

When Propofol Injectable Emulsion 2% is administered to an epileptic patient, there may be a risk of convulsion.

Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously (see section 4.2).

Use is not recommended with electroconvulsive treatment.

As with other anaesthetics sexual disinhibition may occur during recovery.

The benefits and risks of the proposed procedure should be considered prior to proceeding with repeated or prolonged use (>3 hours) of propofol in young children (< 3 years) and in pregnant women as there have been reports of neurotoxicity in preclinical studies, see Section 5.3.

Paediatric population

The use of Propofol Injectable Emulsion is not recommended in newborn infants as this patient population has not been fully investigated. Pharmacokinetic data (see section 5.2) indicate that clearance is considerably reduced in neonates and has a very high inter-individual variability. Relative overdose could occur on administering doses recommended for older children and result in severe cardiovascular depression.

Propofol Injectable Emulsion 2% is not recommended for use in children < 3 years of age due to difficulty in titrating small volumes.

Propofol must not be used in patients of 16 years of age or younger for sedation for intensive care as the safety and efficacy of propofol for sedation in this age group have not been demonstrated (see section 4.3).

Advisory statements concerning Intensive Care Unit management

Use of propofol emulsion infusions for ICU sedation has been associated with a constellation of metabolic derangements and organ system failures that may result in death. Reports have been received of combinations of the following: Metabolic acidosis, Rhabdomyolysis, Hyperkalaemia,

Hepatomegaly, Renal failure, Hyperlipidaemia, Cardiac arrhythmia, Brugada-type ECG (elevated ST-segment and coved T-wave) and rapidly progressive Cardiac failure usually unresponsive to inotropic supportive treatment. Combinations of these events have been referred to as the Propofol Infusion Syndrome. These events were mostly seen in patients with serious head injuries and children with respiratory tract infections who received dosages in excess of those advised in adults for sedation in the intensive care unit.

The following appear to be the major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents - vasoconstrictors, steroids, inotropes and/or Propofol Injectable Emulsion 2% (usually at dose rates greater than 4mg/kg/h for more than 48 hours).

Prescribers should be alert to these events in patients with the above risk factors and immediately discontinue propofol when the above signs develop. All sedative and therapeutic agents used in the intensive care unit (ICU), should be titrated to maintain optimal oxygen delivery and haemodynamic parameters. Patients with raised intra-cranial pressure (ICP) should be given appropriate treatment to support the cerebral perfusion pressure during these treatment modifications

Treating physicians are reminded if possible not to exceed the dosage of 4 mg/kg/h.

Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously.

It is recommended that blood lipid levels should be monitored if propofol is administered to patients thought to be at particular risk of fat overload. Administration of propofol should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the propofol formulation; 1.0 mL of Propofol Injectable Emulsion contains approximately 0.1 g of fat.

Propofol Injectable Emulsion 2% contains 0.0018 mmol sodium per ml. To be taken into consideration by patients on a controlled sodium diet.

Additional Precautions

Caution should be taken when treating patients with mitochondrial disease. These patients may be susceptible to exacerbations of their disorder when undergoing anaesthesia, surgery and ICU care. Maintenance of normothermia, provision of carbohydrates and good hydration are recommended for such patients. The early presentations of mitochondrial disease exacerbation and of the 'propofol infusion syndrome' may be similar.

Propofol Injectable Emulsion contains no antimicrobial preservatives and supports growth of micro-organisms.

EDTA chelates metal ions, including zinc, and reduces microbial growth rates. The need for supplemental zinc should be considered during prolonged administration of Propofol Injectable Emulsion 2%, particularly in patients who are predisposed to zinc deficiency, such as those with burns, diarrhoea and/or major sepsis.

When Propofol Injectable Emulsion 2% is to be aspirated, it must be drawn aseptically into a sterile syringe or giving set immediately after opening the ampoule or breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both Propofol Injectable Emulsion 2% and infusion equipment throughout the infusion period. Any infusion fluids added to the Propofol Injectable Emulsion 2% line must be administered close to the cannula site. Propofol Injectable Emulsion 2% must not be administered via a microbiological filter.

Propofol Injectable Emulsion 2% and any syringe containing Propofol Injectable Emulsion 2% are for single use in an individual patient. In accordance with established guidelines for other lipid emulsions, a single infusion of propofol must not exceed 12 hours. At the end of the procedure or at 12 hours, whichever is the sooner, both the reservoir of propofol and the infusion line must be discarded and replaced as appropriate.

4.5. Interaction with other medicinal products and other forms of interaction

Table 1 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with Pantoprazole Sodium for Injection and instructions for

preventing or managing them.

Consult the labelling of concomitantly used drugs to obtain further information about interactions with PPIs.

4.6.Fertility, pregnancy and lactation Pregnancy

Teratology studies in rats and rabbits showed no teratogenic effects.

The safety of Propofol Injectable Emulsion 2% during pregnancy has not been established. Propofol Injectable Emulsion 2% should not be given to pregnant women except when absolutely necessary. Propofol Injectable Emulsion 2% crosses the placenta and can cause neonatal depression. Propofol Injectable Emulsion 2% can, however, be used during an induced abortion.

Obstetrics

Propofol Injectable Emulsion 2% crosses the placenta and can cause neonatal depression. It should not be used for obstetric anaesthesia.

Breast-feeding

Studies of breastfeeding mothers showed that small quantities of Propofol Injectable Emulsion 2% are excreted in human milk. Women should therefore not breast-feed for 24 hours after administration of Propofol Injectable Emulsion 2%. Milk produced during this period should be discarded.

4.7.Effects on ability to drive and use machines

Propofol Injectable Emulsion 2% has moderate influence on the ability to drive and use machines. Patients should be advised that performance at skilled tasks, such as driving and operating machinery, may be impaired for some time after general anaesthesia.

Propofol Injectable Emulsion 2% induced impairment is not generally detectable beyond 12 hours.

4.8.Undesirable effects

General

Induction and maintenance of anaesthesia or sedation is generally smooth with minimal evidence of excitation.

Side effects during induction, maintenance and recovery occur uncommonly.

The most commonly reported ADRs are pharmacologically predictable side effects of an anaesthetic/sedative agent, such as hypotension. The nature, severity and incidence of adverse events observed in patients receiving Propofol Injectable Emulsion 2% may be related to the condition of the recipients and the operative or therapeutic procedures being undertaken.

The following definitions of frequencies are used:

Very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), very rare ($< 1/10,000$) and not known (cannot be estimated from the available data).

Table of Adverse Drug Reactions

System Organ Class	Frequency	Undesirable Effects
Immune system disorders	Very rare	Anaphylaxis – may include angioedema, bronchospasm, erythema and hypotension
Metabolism and nutrition disorders	Not known ⁽⁹⁾	Metabolic acidosis ⁽⁵⁾ , hyperkalaemia ⁽⁵⁾ , hyperlipidaemia ⁽⁵⁾
Psychiatric disorders	Not known ⁽⁹⁾	Euphoric mood. Drug abuse and drug dependence ⁽⁸⁾
Nervous system disorders	Common	Headache during recovery phase
	Rare	Epileptiform movements, including convulsions and opisthotonus during induction, maintenance and recovery
	Very rare	Postoperative unconsciousness

	Not known ⁽⁹⁾	Involuntary movements
Cardiac disorders	Common	Bradycardia ⁽¹⁾
	Very rare	Pulmonary oedema
	Not known ⁽⁹⁾	Cardiac arrhythmia ⁽⁵⁾ , cardiac failure ⁽⁵⁾ , ⁽⁷⁾
Vascular disorders	Common	Hypotension ⁽²⁾
	Uncommon	Thrombosis and phlebitis
Respiratory, thoracic and mediastinal disorders	Common	Transient apnoea during induction
	Not known ⁽⁹⁾	Respiratory depression (dose dependent)
Gastrointestinal disorders	Common	Nausea and vomiting during recovery phase
	Very rare	Pancreatitis
Hepatobiliary disorders	Not known ⁽⁹⁾	Hepatomegaly ⁽⁵⁾
Musculoskeletal and connective tissue disorders	Not known ⁽⁹⁾	Rhabdomyolysis ⁽³⁾ , ⁽⁵⁾
Renal and urinary disorders	Very rare	Discolouration of urine following prolonged administration
	Not known ⁽⁹⁾	Renal failure ⁽⁵⁾
Reproductive system and breast disorders	Very rare	Sexual disinhibition
General disorders and administration site conditions	Very common	Local pain on induction ⁽⁴⁾
	Very rare	Tissue necrosis ⁽¹⁰⁾ following accidental extravascular administration
	Not known ⁽⁹⁾	Local pain, swelling, following accidental extravascular administration

Investigations	Not known ⁽⁹⁾	Brugada type ECG ^{(5), (6)}
Injury, poisoning and procedural complications	Very rare	Postoperative fever

1. Serious bradycardias are rare. There have been isolated reports of progression to asystole.
2. Occasionally, hypotension may require use of intravenous fluids and reduction of the administration rate of Propofol Injectable Emulsion .
3. Very rare reports of rhabdomyolysis have been received where Propofol Injectable Emulsion has been given at doses greater than 4 mg/kg/hr for ICU sedation.
4. May be minimised by using the larger veins of the forearm and antecubital fossa. With Propofol Injectable Emulsion 1% local pain can also be minimised by the co-administration of lidocaine.
5. Combinations of these events, reported as “Propofol Infusion Syndrome”, may be seen in seriously ill patients who often have multiple risk factors for the development of the events, see section 4.4.
6. Brugada-type ECG - elevated ST-segment and coved T-wave in ECG.
7. Rapidly progressive cardiac failure (in some cases with fatal outcome) in adults. The cardiac failure in such cases was usually unresponsive to inotropic supportive treatment.
8. Abuse of and drug dependence on propofol, predominantly by health care professionals.
9. Not known as it cannot be estimated from the available clinical trial data.
10. Necrosis has been reported where tissue viability has been impaired.

Dystonia/dyskinesia have been reported. Local

The local pain which may occur during the induction phase can be minimised by the use of the larger veins of the forearm and antecubital fossa. Thrombosis and phlebitis are rare.

Accidental

clinical extravasation and animal studies showed minimal tissue reaction. Intra-arterial injection in animals did not induce local tissue effects.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9.Overdose

Accidental overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression would require lowering of the patient's head and, if severe, use of plasma expanders and pressor agents.

5. Pharmacological properties

5.1.Pharmacodynamic properties

Pharmacotherapeutic group: Other general anaesthetics
ATC code: N01AX10

Mechanism of Action

Propofol (2,6-diisopropylphenol) is a short-acting general anaesthetic agent with a rapid onset of action of approximately 30 seconds. Recovery from anaesthesia is usually rapid. The mechanism of action, like all general anaesthetics, is poorly understood. However, propofol is thought to produce its sedative/anaesthetic effects by the positive modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABA_A receptors

Pharmacodynamics effects

In general, falls in mean arterial blood pressure and slight changes in heart rate are observed when Propofol Injectable Emulsion 2% is administered for induction and maintenance of anaesthesia. However, the haemodynamic parameters normally remain relatively stable during maintenance and the incidence of untoward haemodynamic changes is low.

Although ventilatory depression can occur following administration of Propofol Injectable Emulsion 2%, any effects are qualitatively similar to those of other intravenous anaesthetic agents and are readily manageable in clinical practice.

Propofol Injectable Emulsion 2% reduces cerebral blood flow, intracranial pressure and cerebral metabolism. The reduction in intracranial pressure is greater in patients with an elevated baseline intracranial pressure.

Clinical efficacy and safety

Recovery from anaesthesia is usually rapid and clear headed with a low incidence of headache and post-operative nausea and vomiting.

In general, there is less post-operative nausea and vomiting following anaesthesia with Propofol Injectable Emulsion 2% than following anaesthesia with inhalational agents. There is evidence that this may be related to a reduced emetic potential of propofol.

Propofol Injectable Emulsion 2%, at the concentrations likely to occur clinically, does not inhibit the synthesis of adrenocortical hormones.

Paediatric population

Limited studies on the duration of propofol based anaesthesia in children indicate safety and efficacy is unchanged up to duration of 4 hours. Literature evidence of use in children documents use for prolonged procedures without changes in safety or efficacy.

5.2. Pharmacokinetics properties

Absorption

When Propofol Injectable Emulsion 2% is used to maintain anaesthesia, blood concentrations asymptotically approach the steady-state value for the given administration rate.

Distribution

Propofol is extensively distributed and rapidly cleared from the body (total body clearance 1.5-2 litres/minute).

Elimination

The decline in propofol concentrations following a bolus dose or following the termination of an infusion can be described by a three compartment open model with very rapid distribution (half-life 2-4 minutes), rapid elimination (half-life 30-60 minutes), and a slower final phase, representative of redistribution of propofol from poorly perfused tissue.

Clearance occurs by metabolic processes, mainly in the liver where it is blood flow dependent, to form inactive conjugates of propofol and its corresponding quinol, which are excreted in urine.

After a single dose of 3 mg/kg intravenously, propofol clearance/kg body weight increased with age as follows: Median clearance was considerably lower in neonates <1 month old (n=25) (20 ml/kg/min) compared to older children (n= 36, age range 4 months-7 years). Additionally inter-individual variability was considerable in neonates (range 3.7-78 ml/kg/min). Due to this limited trial data that indicates a large variability, no dose recommendations can be given for this age group.

Median propofol clearance in older aged children after a single 3 mg/kg bolus was 37.5 ml/min/kg (4-24 months) (n=8), 38.7 ml/min/kg (11-43 months) (n=6), 48 ml/min/kg (1-3 years)(n=12), 28.2 ml/min/kg (4-7 years)(n=10) as compared with 23.6 ml/min/kg in adults (n=6).

Linearity

The pharmacokinetics are linear over the recommended range of infusion rates of Propofol Injectable Emulsion 2%.

5.3 Preclinical safety data

Published studies in animals demonstrate that the use of anaesthetic agents during the period of rapid brain growth or synaptogenesis results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester through the first several months of life, but may extend out to approximately 3 years of age in humans.

In neonatal primates, exposure to 3 hours of an anaesthetic regimen that produced a light surgical plane of anaesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer increased neuronal cell loss. Data in foetal and neonatal rodents and primates suggest that the neuronal and oligodendrocyte cell losses are associated with subtle but prolonged cognitive deficits in learning and memory. The clinical significance of these preclinical findings is not known, and healthcare providers should balance the benefits of appropriate anaesthesia in young children less than 3 years of age and pregnant women who require procedures against the potential risks suggested by the preclinical data.

Propofol is a drug on which extensive clinical experience has been obtained. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics

6. Pharmaceutical particulars

6.1. List of excipients

Refined Soya bean oil IV USP, Glycerol Anhydrous USP, Purified egg yolk lecithin, Edetate disodium USP, Sodium hydroxide and Water for Injection.

6.2. Incompatibilities

Not applicable.

6.3. Shelf life

24 months

6.4. Special precautions for storage

Store between 4° to 25°C

6.5. Nature and contents of container

Glass Vials: 10 mL clear USP Type I tubular glass vial.

6.6. Special precautions for disposal and other handling

For single use. Discard any unused contents.

7. Marketing Authorization Holder

M/s. ASPIRO PHARMA LTD

Survey No. 321, Biotech Park, Phase-III, Karkapatla,

Markook Mandal, Siddipet District - 502281, Telangana, India

Manufacturing site

M/s. Hetero Labs Limited, 7-2-A2, Hetero Corporate,
Industrial Estates, Sanath Nagar, Hyderabad-500 018, Telangana, INDIA.

8. Marketing Authorization Number

TAN 22 HM 0249

9. Date of first authorization/renewal of authorization

19th July, 2022

10. Date of revision of the text

11. Category for Distribution

PP – ‘Prescription preparation’.